TEXT SEARCHABLE DOCUMENT



Data Evaluation Record on method validation for metconazole and its transformation products M11, M21, M30 and triazole in soil

PMRA Submission Number {.....}

EPA MRID Number 46902210

Data Requirement:

PMRA Data Code:

EPA DP Barcode:

D331927

OECD Data Point:

EPA Guideline:

OPPTS 850.7100.

Test material:

Common name:

Metconazole.

Chemical name:

IUPAC name:

(1RS,5RS,1RS,5SR)-5-(4-Chlorobenzyl)-2,2-dimethyl-1-(1H-1,2,4-

triazol-1-ylmethyl)cyclopentanol.

(1RS,5RS[cis isomer];1RS,5SR[trans isomer])-5-(4-chlorobenzyl)-2,2-

dimethyl-1-(1H-1,2,4-triazol-1-vlmethyl) cyclopentanol.

CAS name:

5-[(4-Chlorophenyl)methyl]-2,2-dimethyl-1-(1H-1,2,4-triazol-1-

ylmethyl)cyclopentanol.

125116-23-6.

CAS No.: Synonyms:

BAS 555 F; CL 354,801 (cis); CL 354,802 (trans); AC 900,768; WL

148,271; Caramba; CL900768; KNF-S-474; M0.

Smiles string:

c1cc(Cl)ccc1CC2CCC(C)(C)C2(O)CN3N=CN=C3 (EPI Suite, v3.12

SMILES String).

Primary Reviewer: Lynne Binari

Signature:

Cambridge Environmental

Date: 1/16/07

Secondary Reviewer: Kathleen Ferguson

Signature:

Cambridge Environmental

Date: 1/16/07

QC/QA Manager: Joan Gaidos

Signature:

Cambridge Environmental

Date: 1/16/07

2/)0/86

Final Reviewer: James Lin

Signature:

EPA Reviewer

Date:

Company Code:

Active Code:

Use Site Category:

EPA PC Code:

125619.

CITATION: Ibrahim, A. and R. Hauser. 2006. Independent method validation of BASF analytical method D0506: method for determination of metconazole (BAS 555 F) and its metabolites M11, M21, M30 and triazol in soil using LC/MS/MS. Unpublished study performed

PMRA Submission Number {.....}

EPA MRID Number 46902210

Data Requirement:

PMRA Data Code:

EPA DP Barcode:

D331927

OECD Data Point:

EPA Guideline:

OPPTS 850.7100.

Test material:

Common name:

Metconazole.

Chemical name:

IUPAC name:

(1RS,5RS,1RS,5SR)-5-(4-Chlorobenzyl)-2,2-dimethyl-1-(1H-1,2,4-

triazol-1-ylmethyl)cyclopentanol.

(1RS,5RS[cis isomer];1RS,5SR[trans isomer])-5-(4-chlorobenzyl)-2,2-

dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl) cyclopentanol.

CAS name:

5-[(4-Chlorophenyl)methyl]-2,2-dimethyl-1-(1H-1,2,4-triazol-1-

ylmethyl)cyclopentanol.

CAS No.:

125116-23-6.

Synonyms:

BAS 555 F; CL 354,801 (cis); CL 354,802 (trans); AC 900,768; WL

148,271; Caramba; CL900768; KNF-S-474; M0.

Smiles string:

c1cc(Cl)ccc1CC2CCC(C)(C)C2(O)CN3N=CN=C3 (EPI Suite, v3.12

SMILES String).

Primary Reviewer: Lynne Binari

Signature: Lynne Binari
Date: 1/16/07

Signature: Kathlein Jegurn
Date: 1/16/07

Signature:

Cambridge Environmental

Secondary Reviewer: Kathleen Ferguson

Cambridge Environmental

QC/QA Manager: Joan Gaidos

Signature:

Cambridge Environmental

Date: 1/16/07

Final Reviewer: Amer Al-Mudallal

Signature:

EPA Reviewer

Date:

Company Code:

Active Code:

Use Site Category:

EPA PC Code:

125619.

CITATION: Ibrahim, A. and R. Hauser. 2006. Independent method validation of BASF analytical method D0506: method for determination of metconazole (BAS 555 F) and its metabolites M11, M21, M30 and triazol in soil using LC/MS/MS. Unpublished study performed

PMRA Submission Number {.....}

EPA MRID Number 46902210

by ADPEN Laboratories, Inc., Jacksonville, Florida; sponsored and submitted by BASF Corporation, Research Triangle Park, North Carolina. ADPEN Study No.: 2K6-238588 (p. 7). BASF Study No.: 238588 and Registration Document No.: 2006/7007031 (pp. 1, 7). Experimental start date March 17, 2006, and termination date March 30, 2006 (p. 7). Final report issued June 21, 2006.

PMRA Submission Number {.....}

EPA MRID Number 46902210

EXECUTIVE SUMMARY

An independent laboratory validation of a method used to detect and quantify (1RS,5RS[cis];1RS,5SR[trans])-5-(4-chlorobenzyl)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (metconazole, BAS 555 F) and its transformation products

- (1RS,5SR-5-[R-(4-chlorobenzyl)(hydroxy) methyl]-2,2-dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (R benzylic alcohol, M11, KNF-474-M-11, CL 382390),
- (1RS,5RS-5-[R-(4-chlorobenzyl)(hydroxy) methyl]-2,2-dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl) cyclopentanol (R benzyl alcohol, M21, KNF-474-M-21, CL 382391),
- methanone,4-chlorophenyl-[2-hydroxy-3,3-dimethyl-2-(1H-1,2,4-triazol-1-ylmethyl) cyclopentyl]-,cis-(±)-(9Cl) (R benzyl ketone, M30, KNF-474-M-30, CL 382389), and
- 1,2,4-(1H)-triazole (triazole, BF 480-16, CL 196719)

in soil was performed to support registration of metconazole (p. 7; Figure 1, pp. 22-24; Appendix 3, pp. 97-98). This method validation was conducted in accordance with USEPA OPPTS 850.7100 "Public Draft" - Data Reporting Guideline for Environmental Chemistry Methods and in compliance with 40 CFR Part 160 GLP Standards (p. 3; Appendix 3, pp. 87-88). Aliquots (10 \pm 0.1 g) of loamy sand soil (0-15 cm, pH 7.0, organic matter 0.7%, clay 10%, bulk density 1.23 g/cm³, CEC 6.7 meq/100 g, moisture at 1/3 bar 6.9%; Table VII, p. 36 of MRID 46902206) from Oklahoma were weighed into 250-mL centrifuge bottles, then cis-metconazole (purity ≥98.8%, Lot/Batch No.: AC8879-136A; trans BAS 555 F, purity ≥98.6%, Lot/Batch No.: AC9339-122A). M11 (purity 98.5%, Lot/Batch No.: AS 2106a), M21 (purity 98.3%, Lot/Batch No.; AS 2110a), M30 (purity 98.4%, Lot/Batch No.: AS 2111a) and triazole (purity 99.0%, Lot/Batch No.: AC10194-134) were each applied at 10 and 100 ug a.i./kg (five treated soil samples per application rate; pp. 10-11; Appendix 2, pp. 72-79; Appendix 3, pp. 102-103). Metconazole (cis, trans), M11, M21 and M30 in acetone were applied as a mixed fortification solution, while triazole in 0.05% aqueous formic acid was applied separately; all application solution volumes were 0.1 mL (Appendix 3, pp. 102-103). Fortified soil samples were extracted once with methanol:0.2N HCl (90:10, v:v) followed by once with methanol:0.2N HCl (50:50, v:v): extraction solvent volumes were 100 mL (p. 11; Appendix 3, p. 103). Each extraction was done using a reciprocal shaker (moderate speed, rpm not specified) for 60 minutes for the initial extraction and 20 minutes for the second extraction, then extract and soil were separated via centrifugation (ca. 5,000 rpm, 10 minutes). Aliquots (10 mL) of each extract were combined and centrifuged (ca. 2,000 rpm, 10 minutes).

For determination of cis/trans-metconazole, M11, M21 and M30, an aliquot (2 mL) of the combined extract sample was diluted with aqueous 0.05% formic acid:methanol (60:40, v:v, 3 mL), vortexed and analyzed by LC/MS/MS under the following conditions: Phenomenex Luna C18 LC column [4.6 x 150 mm, 5 μm (reported 6 mm diameter typographical error)], gradient mobile phase combining (A) 0.1% aqueous formic acid and (B) 0.1% formic acid in acetonitrile [percent A:B at 0.0 min. 90:10 (v:v), 6.5 min. 30:70, 10.5 min. 10:90, 10.6-13.0 min. 90:10], injection volume 20 μL, flow rate 1.0 mL/minute, PE Sciex API 4000 MS, turbo ion spray

PMRA Submission Number {.....}

EPA MRID Number 46902210

interface, ion mode positive, multiple reaction monitoring (Table 2, p. 20; Appendix 3, pp. 103-104).

For determination of triazole an aliquot (2 mL) of the extract was diluted with water (1 mL) and partitioned once (2 mL) with methylene chloride (p. 11, Appendix 3, p. 104). The resulting aqueous phase was taken to dryness (N-Evaporator, 45°C), then the resulting residues were reconstituted in water (2 mL) via vortex, centrifuged (*ca.* 2,000 rpm, 10 minutes) and analyzed by LC/MS/MS under the following conditions: Thermo Hypercarb column (4.6 x 50 mm, 3 μm), gradient mobile phase combining (A) 1% aqueous formic acid and (B) 1% formic acid in methanol [percent A:B at 0.0-2.0 min. 95:5 (v:v), 2.5-5.0 min. 10:90, 5.1-7.0 min. 95:5], injection volume 30 μL, flow rate 0.8 mL/minute, PE Sciex API 4000 MS, turbo ion spray interface, ion mode positive, multiple reaction monitoring (Table 2, p. 21; Appendix 3, pp. 105, 110).

Metconazole (cis/trans), M11, M21, M30 and triazole extracted from the fortified samples were identified by comparison to the retention times of reference standards (Figure 4, pp. 29-52; Figure 5, pp. 55-56, 58, 60, 62, 64). The limits of quantitation (LOQ) and detection (LOD) were set at 10 μg a.i./kg and 0.1 ng/mL, respectively for all test compounds (p. 11).

Overall recoveries from soil fortified at 10 and 100 μ g a.i./kg averaged (n = 10) 98.7 \pm 3.46% (range 93.8-105.8%) of the applied for cis-metconazole, $100.0 \pm 5.33\%$ (93.8-113.8%) for transmetconazole, $108.8 \pm 5.06\%$ (102.0-118.3%) for M11, $102.7 \pm 4.81\%$ (93.5-110.8%) for M21, $112.9 \pm 5.69\%$ (100.8-120.8%) for M30 and $85.9 \pm 11.56\%$ (65.2-112.7%) for triazole (DER Attachment 1). Recoveries at the 10 µg a.i./kg and 100 µg a.i./kg fortification levels averaged (n = 5) $100.1 \pm 3.68\%$ (95.8-105.8%) and $97.3 \pm 2.55\%$ (93.8-100.8%), respectively, for cismetconazole, $99.2 \pm 3.25\%$ (93.8-103.0%) and $100.9 \pm 6.68\%$ (95.5-113.8%), respectively, for trans-metconazole, $108.5 \pm 6.69\%$ (102.0-118.3%) and $109.1 \pm 2.53\%$ (105.3-112.3%), respectively, for M11, 99.3 \pm 4.08% (93.5-104.0%) and 106.1 \pm 2.54% (103.0-110.8%), respectively, for M21, $112.1 \pm 7.01\%$ (100.8-120.8%) and $113.7 \pm 3.79\%$ (107.8-118.3%), respectively, for M30, and $92.5 \pm 10.94\%$ (80.0-112.7%) and $79.3 \pm 7.74\%$ (65.2-87.3%). respectively, for triazole. Detector responses were linear for cis-meteonazole ($r^2 = 0.9999$). trans-metconazole ($r^2 = 0.9984$), M11 ($r^2 = 0.9995$), M21 ($r^2 = 0.9997$) and M30 ($r^2 = 1.000$) over a range of 2-1,000 pg (0.1-50 ng/mL, based on 20 μ L injection volume) and also for triazole $(r^2 = 0.9983)$ over a range of 7.5-300 pg (0.25-10 ng/mL, based on 30 μ L injection volume; Appendix 1, pp. 66-71). Chromatograms of reagent blank and unfortified control soil samples indicated there were no significant interfering peaks at the retention times for cis/transmetconazole and its products M11, M21, M30 and triazole (Figure 5, pp. 53-54, 57, 59, 61, 63).

PMR A	Submission Number	[}
T TATITY	Dubilibaton runnoci	6

EPA MRID Number 46902210

Attachment 1: Structure of Parent Compound and Transformation Products

PMRA Submission Number {.....}

EPA MRID Number 46902210

Metconazole [BAS 555 F; CL 354,801 (cis); CL 354,802 (trans); AC 900,768; WL 148,271; Caramba; CL 900768; KNF-S-474; M0]

IUPAC Name: (1RS,5RS,1RS,5SR)-5-(4-Chlorobenzyl)-2,2-dimethyl-1-(1H-1,2,4-triazol-

1-ylmethyl)cyclopentanol.

CAS Name: 5-[(4-Chlorophenyl)methyl]-2,2-dimethyl-1-(1*H*-1,2,4-triazol-1-

ylmethyl)cyclopentanol.

CAS Number: 125116-23-6

SMILES String: c1cc(Cl)ccc1CC2CCC(C)(C)C2(O)CN3N=CN=C3 (EPI Suite, v3.12

SMILES String).

Cis-metconazole

Trans-metconazole

PMRA Submission Number {.....}

EPA MRID Number 46902210

(1RS,5SR-5-[R-(4-Chlorobenzyl)(hydroxy) methyl]-2,2-dimethyl-1-(1H-1,2,4-triazol-1-yl-methyl)cyclopentanol [CL382390; M11; KNF-474-M-11; R Benzylic alcohol]

IUPAC Name:

Not reported.

CAS Name:

Not reported.

CAS Number:

Not reported.

(1RS,5RS-5-[R-(4-Chlorobenzyl)(hydroxy) methyl]-2,2-dimethyl-1-(1H-1,2,4-triazol-1-yl-methyl)cyclopentanol [CL382391; M21; KNF-474-M-21; R Benzyl alcohol]

IUPAC Name:

Not reported.

CAS Name:

Not reported.

CAS Number:

Not reported.

PMRA Submission Number {.....}

EPA MRID Number 46902210

2-Hydroxy-3,3-dimethyl-2-[1,2,4]triazol-1-ylmethyl-cyclopentyl-(4-chlorophenyl)-methanone [CL382389; M30; KNF-474-M-30; R Benzyl Ketone]

IUPAC Name:

Not reported.

CAS Name:

Not reported.

CAS Number:

Not reported.

1,2,4-(1H)-Triazole [Triazol; BF 480-16; CL 196719]

IUPAC Name:

Not reported.

CAS Name:

Not reported.

CAS Number:

Not reported.



Attachment 2: Excel Spreadsheets

Chemical: Metconazole (BAS 555 F)

PC: 125619 MRID: 46902210

Guideline: OPPTS 850.7100

Method validation for metconazole (cis/trans-BAS 555 F) and its products M11, M21, M30 and triazole in Oklahoma loamy sand soil. Confirmation of means/standard deviations for applied metconazole and its products.

	cis-Metconazole				trans-Metconazole				M11			
Fortified	Measured	Recovery	Mean	Std. dev. ¹	Measured	Recovery	Mean	Std. dev. ¹	Measured	Recovery	Mean	Std. dev. ¹
(ppb)	(ppb)	(%)	(%)	(%)	(ppb)	(%)	(%)	(%)	(ppb)	(%)	(%)	(%)
10		97.3			9.375	93.8			10.475	104.8		
	9.875	98.8			9.850	98.5			11.825	118.3		
	10.275	102.8		*	10.300	103.0			10.200	102.0		
	10.575	105.8			10.200	102.0			11.475	114.8		
	9.575	95.8	100.1	3.68	9.850	98.5	99.2	3.25	10.275	102.8	108.5	6.69
100	95.250	95.3			113.750	113.8		-	105.250	105.3	-	
	100.750	100.8			101.000	101.0			112.250	112.3		
	99.250	99.3			96.750	96.8		;	109.500	109.5		
	93.750	93.8			95.500	95.5			107.250	107.3		
	97.250	97.3	97.3	2.55	97.500	97.5	100.9	6.68	111.000	111.0	109.1	2.53
Overall mean		98.7				100.0				108.8	i s	
std.dev.		3.46				5.33				5.06		
maximum		105.8				113.8				118.3		
minimum		93.8				93.8				102.0		
n =		10				10		وعوا الماميونية	The second second	10		
M21			M30				Triazole					
Fortified	Measured	Recovery		Std. dev. ¹	Measured			Std. dev.1	Measured			Std. dev. ¹
(ppb)	Measured (ppb)	(%)	Mean (%)	Std. dev. ¹ (%)	Measured (ppb)	Recovery (%)	Mean (%)	Std. dev. ¹ (%)	Measured (ppb)	Recovery (%)	Mean (%)	Std. dev. ¹ (%)
						(%) 111.5						
(ppb)	(ppb) 10.250 10.100	(%)			(ppb) 11.150 10.075	(%)			(ppb)	(%)		
(ppb)	(ppb) 10.250 10.100 10.400	(%) 102.5 101.0 104.0			(ppb) 11.150 10.075 11.800	(%) 111.5			(ppb) 11.267	(%) 112.7		
(ppb)	(ppb) 10.250 10.100 10.400 9.350	(%) 102.5 101.0 104.0 93.5	(%)	(%)	(ppb) 11.150 10.075	(%) 111.5 100.8			(ppb) 11.267 8.000 8.867 8.800	(%) 112.7 80.0 88.7 88.0		
(ppb) 10	(ppb) 10.250 10.100 10.400	(%) 102.5 101.0 104.0		(%)	(ppb) 11.150 10.075 11.800	(%) 111.5 100.8 118.0		(%)	(ppb) 11.267 8.000 8.867 8.800	(%) 112.7 80.0 88.7		
(ppb)	(ppb) 10.250 10.100 10.400 9.350	(%) 102.5 101.0 104.0 93.5	(%)	(%)	(ppb) 11.150 10.075 11.800 12.075	(%) 111.5 100.8 118.0 120.8	(%)	(%)	(ppb) 11.267 8.000 8.867 8.800	(%) 112.7 80.0 88.7 88.0	(%)	(%)
(ppb) 10	(ppb) 10.250 10.100 10.400 9.350 9.550	(%) 102.5 101.0 104.0 93.5 95.5	(%)	(%)	(ppb) 11.150 10.075 11.800 12.075 10.950	(%) 111.5 100.8 118.0 120.8 109.5	(%)	(%)	(ppb) 11.267 8.000 8.867 8.800 9.333	(%) 112.7 80.0 88.7 88.0 93.3	(%)	(%)
(ppb) 10	(ppb) 10.250 10.100 10.400 9.350 9.550 105.750 105.250 105.750	(%) 102.5 101.0 104.0 93.5 95.5	(%)	(%)	(ppb) 11.150 10.075 11.800 12.075 10.950	(%) 111.5 100.8 118.0 120.8 109.5	(%)	(%)	(ppb) 11.267 8.000 8.867 8.800 9.333 87.333	(%) 112.7 80.0 88.7 88.0 93.3 87.3	(%)	(%)
(ppb) 10	(ppb) 10.250 10.100 10.400 9.350 9.550 105.750 105.250	(%) 102.5 101.0 104.0 93.5 95.5 105.8 105.3	(%)	4.08	(ppb) 11.150 10.075 11.800 12.075 10.950 107.750 118.250	(%) 111.5 100.8 118.0 120.8 109.5 107.8 118.3	(%)	(%)	(ppb) 11.267 8.000 8.867 8.800 9.333 87.333 83.333	(%) 112.7 80.0 88.7 88.0 93.3 87.3 83.3	(%)	(%)
(ppb) 10 100	(ppb) 10.250 10.100 10.400 9.350 9.550 105.750 105.250 105.750	(%) 102.5 101.0 104.0 93.5 95.5 105.8 105.3 105.8	(%)	(%)	(ppb) 11.150 10.075 11.800 12.075 10.950 107.750 118.250 114.000	(%) 111.5 100.8 118.0 120.8 109.5 107.8 118.3 114.0	(%)	(%)	(ppb) 11.267 8.000 8.867 8.800 9.333 87.333 83.333 83.333 65.200	(%) 112.7 80.0 88.7 88.0 93.3 87.3 83.3 83.3	(%)	(%)
(ppb) 10	(ppb) 10.250 10.100 10.400 9.350 9.550 105.750 105.250 105.750 103.000	(%) 102.5 101.0 104.0 93.5 95.5 105.8 105.3 105.8 103.0	99.3	4.08	(ppb) 11.150 10.075 11.800 12.075 10.950 107.750 118.250 114.000 111.500	(%) 111.5 100.8 118.0 120.8 109.5 107.8 118.3 114.0 111.5	112.1	7.01	(ppb) 11.267 8.000 8.867 8.800 9.333 87.333 83.333 83.333 65.200	(%) 112.7 80.0 88.7 88.0 93.3 87.3 83.3 83.3 65.2	92.5	10.94
(ppb) 10	(ppb) 10.250 10.100 10.400 9.350 9.550 105.750 105.250 105.750 103.000	(%) 102.5 101.0 104.0 93.5 95.5 105.8 105.3 105.8 103.0 110.8	99.3	4.08	(ppb) 11.150 10.075 11.800 12.075 10.950 107.750 118.250 114.000 111.500	(%) 111.5 100.8 118.0 120.8 109.5 107.8 118.3 114.0 111.5 117.0	112.1	7.01	(ppb) 11.267 8.000 8.867 8.800 9.333 87.333 83.333 83.333 65.200	(%) 112.7 80.0 88.7 88.0 93.3 87.3 83.3 83.3 65.2 77.3	92.5	10.94
(ppb) 10 100 Overall mean std.dev. maximum	(ppb) 10.250 10.100 10.400 9.350 9.550 105.750 105.250 105.750 103.000	(%) 102.5 101.0 104.0 93.5 95.5 105.8 105.3 105.8 103.0 110.8	99.3	4.08	(ppb) 11.150 10.075 11.800 12.075 10.950 107.750 118.250 114.000 111.500	(%) 111.5 100.8 118.0 120.8 109.5 107.8 118.3 114.0 111.5 117.0	112.1	7.01	(ppb) 11.267 8.000 8.867 8.800 9.333 87.333 83.333 83.333 65.200	(%) 112.7 80.0 88.7 88.0 93.3 87.3 83.3 83.3 65.2 77.3	92.5	10.94
(ppb) 10 100 Overall mean std.dev.	(ppb) 10.250 10.100 10.400 9.350 9.550 105.750 105.250 105.750 103.000	(%) 102.5 101.0 104.0 93.5 95.5 105.8 105.3 105.8 103.0 110.8	99.3	4.08	(ppb) 11.150 10.075 11.800 12.075 10.950 107.750 118.250 114.000 111.500	(%) 111.5 100.8 118.0 120.8 109.5 107.8 118.3 114.0 111.5 117.0 112.9 5.69	112.1	7.01	(ppb) 11.267 8.000 8.867 8.800 9.333 87.333 83.333 83.333 65.200	(%) 112.7 80.0 88.7 88.0 93.3 87.3 83.3 65.2 77.3 85.9 11.56	92.5	10.94

¹Standard deviations determined using "biased" or "n" method for entire sample population; study authors used "nonbiased" or "n-1" method. Results from Appendix 1, pp. 66-71 of the study report.

Means and standard deviations calculated using Microsoft programs functions @average (A1:A2) and @stdevp(A1:A2).